Literature DB >> 3126633

Transdermal nitroglycerin patches for silent myocardial ischemia during antianginal treatment.

A Schneeweiss1, A Marmor.   

Abstract

Because silent ischemia is not associated with an increase in heart rate and, being asymptomatic, its treatment requires constant therapeutic plasma levels of the drug used, a transdermal nitroglycerin patch (Deponit) was selected for treatment of this condition. Eight patients with documented silent ischemia were studied. All patients also had angina on effort treated with calcium antagonists (n = 8) and beta blockers (n = 6). They were evaluated by 24-hour ambulatory electrocardiographic monitoring. The transdermal nitroglycerin patch, 20 to 30 mg/24 hours, reduced the number of silent ischemic episodes from 9.25 +/- 5.52 to 2.4 +/- 2.0 episodes per 24 hours (p less than 0.001). The maximal ST-segment depression was reduced from 3.1 +/- 0.7 to 0.9 +/- 0.7 mm (p less than 0.001). Ventricular premature beats were significantly reduced, by 50%. Symptomatic ischemic episodes were completely suppressed. Thus, transdermal nitroglycerin, in moderate doses, is effective in suppressing silent ischemia in patients with angina pectoris who have silent ischemic episodes despite treatment with other antianginal agents.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126633     DOI: 10.1016/0002-9149(88)90088-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Daily life cardiac ischaemia. Should it be treated?

Authors:  B D Bertolet; C J Pepine
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 4.  Nitrates in silent ischemia.

Authors:  H Purcell; D Mulcahy; K Fox
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

5.  The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.